tiprankstipranks
Neurocrine Biosciences, Inc. Shs Unsponsored Brazilian Depositary Receipt Repr 0.05 Sh (BR:N1BI34)
:N1BI34
Brazil Market
N1BI34
Neurocrine Biosciences, Inc. Shs Unsponsored Brazilian Depositary Receipt Repr 0.05 Sh
RESEARCH TOOLSreports

Neurocrine Biosciences, Inc. Shs Unsponsored Brazilian Depositary Receipt Repr 0.05 Sh (N1BI34) Price & Analysis

1 Followers

N1BI34 Stock Chart & Stats

R$42.92
-R$1.56(-3.51%)
―
--
Day’s Range― - ―
52-Week RangeR$27.38 - R$47.10
Previous CloseN/A
VolumeN/A
Average Volume (3M)63.00
Market Cap
R$85.13B
Enterprise ValueR$84.09K
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)24577.3
Beta-0.08
Next Earnings
Nov 03, 2026
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.00
Shares Outstanding100,549,980
10 Day Avg. Volume30
30 Day Avg. Volume63
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A

Neurocrine Biosciences, Inc. Shs Unsponsored Brazilian Depositary Receipt Repr 0.05 Sh News

Neurocrine price target raised to $194 from $185 at Wedbush
Neurocrine price target raised to $194 from $185 at Wedbush
Wedbush raised the firm’s price target on Neurocrine (NBIX) to $194 from $185 and keeps an Outperform rating...
2d ago
NBIX
Neurocrine price target raised to $210 from $200 at Canaccord
Neurocrine price target raised to $210 from $200 at Canaccord
Canaccord analyst Sumant Kulkarni raised the firm’s price target on Neurocrine (NBIX) to $210 from $200 and keeps...
2d ago
NBIX
Neurocrine price target raised to $249 from $246 at Citi
Neurocrine price target raised to $249 from $246 at Citi
Citi analyst Yigal Nochomovitz raised the firm’s price target on Neurocrine (NBIX) to $249 from $246 and keeps...
5d ago
NBIX
Wells Fargo recommends buying Neurocrine on weakness after solid quarter
Wells Fargo recommends buying Neurocrine on weakness after solid quarter
Wells Fargo thinks Neurocrine (NBIX) stock’s weakness today despite a “solid beat and raise quarter” last night is...
5d ago
NBIX
Neurocrine price target raised to $196 from $193 at Morgan Stanley
Neurocrine price target raised to $196 from $193 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Neurocrine (NBIX) to $196 from $193 and keeps an Equal...
5d ago
NBIX
Neurocrine price target raised to $220 from $200 at TD Cowen
Neurocrine price target raised to $220 from $200 at TD Cowen
TD Cowen analyst Phil Nadeau raised the firm’s price target on Neurocrine (NBIX) to $220 from $200 and...
5d ago
NBIX
Neurocrine price target raised to $190 from $170 at Deutsche Bank
Neurocrine price target raised to $190 from $170 at Deutsche Bank
Deutsche Bank analyst David Hoang raised the firm’s price target on Neurocrine (NBIX) to $190 from $170 and...
5d ago
NBIX
Neurocrine price target raised to $214 from $199 at BofA
Neurocrine price target raised to $214 from $199 at BofA
BofA raised the firm’s price target on Neurocrine (NBIX) to $214 from $199 and keeps a Buy rating...
5d ago
NBIX
Neurocrine price target raised to $215 from $210 at Cantor Fitzgerald
Neurocrine price target raised to $215 from $210 at Cantor Fitzgerald
Cantor Fitzgerald raised the firm’s price target on Neurocrine (NBIX) to $215 from $210 and keeps an Overweight...
5d ago
NBIX
Neurocrine price target raised to $204 from $200 at Needham
Neurocrine price target raised to $204 from $200 at Needham
Needham raised the firm’s price target on Neurocrine (NBIX) to $204 from $200 and keeps a Buy rating...
5d ago
NBIX
Neurocrine Biosciences: Strong Q2 Execution, Expanded Pipeline, and Multi-Billion-Dollar Peak Sales Potential Support Buy Rating
Neurocrine Biosciences: Strong Q2 Execution, Expanded Pipeline, and Multi-Billion-Dollar Peak Sales Potential Support Buy Rating
William Blair analyst Myles Minter has reiterated their bullish stance on NBIX stock, giving a Buy rating today....
5d ago
NBIX
Neurocrine Biosciences: Strong Q2 Beat, Upgraded Outlook, and Price Target Raised to $204 Support Buy Rating
Neurocrine Biosciences: Strong Q2 Beat, Upgraded Outlook, and Price Target Raised to $204 Support Buy Rating
Ami Fadia, an analyst from Needham, assigned the Buy rating on Neurocrine. The associated price target was raised...
5d ago
NBIX

N1BI34 FAQ

What was Neurocrine Biosciences, Inc. Shs Unsponsored Brazilian Depositary Receipt Repr 0.05 Sh’s price range in the past 12 months?
Neurocrine Biosciences, Inc. Shs Unsponsored Brazilian Depositary Receipt Repr 0.05 Sh lowest stock price was R$27.38 and its highest was R$47.10 in the past 12 months.
    What is Neurocrine Biosciences, Inc. Shs Unsponsored Brazilian Depositary Receipt Repr 0.05 Sh’s market cap?
    Neurocrine Biosciences, Inc. Shs Unsponsored Brazilian Depositary Receipt Repr 0.05 Sh’s market cap is R$85.13B.
      When is Neurocrine Biosciences, Inc. Shs Unsponsored Brazilian Depositary Receipt Repr 0.05 Sh’s upcoming earnings report date?
      Neurocrine Biosciences, Inc. Shs Unsponsored Brazilian Depositary Receipt Repr 0.05 Sh’s upcoming earnings report date is Nov 03, 2026 which is in 90 days.
        How were Neurocrine Biosciences, Inc. Shs Unsponsored Brazilian Depositary Receipt Repr 0.05 Sh’s earnings last quarter?
        Neurocrine Biosciences, Inc. Shs Unsponsored Brazilian Depositary Receipt Repr 0.05 Sh released its earnings results on Jul 30, 2026. The company reported R$0 earnings per share for the quarter, the consensus estimate of N/A by R$0.
          Is Neurocrine Biosciences, Inc. Shs Unsponsored Brazilian Depositary Receipt Repr 0.05 Sh overvalued?
          According to Wall Street analysts Neurocrine Biosciences, Inc. Shs Unsponsored Brazilian Depositary Receipt Repr 0.05 Sh’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
            Does Neurocrine Biosciences, Inc. Shs Unsponsored Brazilian Depositary Receipt Repr 0.05 Sh pay dividends?
            Neurocrine Biosciences, Inc. Shs Unsponsored Brazilian Depositary Receipt Repr 0.05 Sh does not currently pay dividends.
            What is Neurocrine Biosciences, Inc. Shs Unsponsored Brazilian Depositary Receipt Repr 0.05 Sh’s EPS estimate?
            Neurocrine Biosciences, Inc. Shs Unsponsored Brazilian Depositary Receipt Repr 0.05 Sh’s EPS estimate for its next earnings report is not yet available.
            How many shares outstanding does Neurocrine Biosciences, Inc. Shs Unsponsored Brazilian Depositary Receipt Repr 0.05 Sh have?
            Neurocrine Biosciences, Inc. Shs Unsponsored Brazilian Depositary Receipt Repr 0.05 Sh has 100,549,980 shares outstanding.
              What happened to Neurocrine Biosciences, Inc. Shs Unsponsored Brazilian Depositary Receipt Repr 0.05 Sh’s price movement after its last earnings report?
              Neurocrine Biosciences, Inc. Shs Unsponsored Brazilian Depositary Receipt Repr 0.05 Sh reported an EPS of R$0 in its last earnings report, expectations of N/A. Following the earnings report the stock price went same 0%.
                Which hedge fund is a major shareholder of Neurocrine Biosciences, Inc. Shs Unsponsored Brazilian Depositary Receipt Repr 0.05 Sh?
                Currently, no hedge funds are holding shares in BR:N1BI34
                What is the TipRanks Smart Score and how is it calculated?
                Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

                  Neurocrine Biosciences, Inc. Shs Unsponsored Brazilian Depositary Receipt Repr 0.05 Sh (N1BI34) Earnings & Revenues

                  Historic Earnings Reports
                  Similar Stocks
                  Company
                  Price & Change
                  Follow
                  A1SN34
                  Ascendis Pharma ADR Unsponsored Brazilian Depositary Receipt Repr 0.0666 ADR
                  ―
                  ―
                  B1NT34
                  BioNTech SE ADR Unsponsored Brazilian Depositary Receipt Repr 0.0625 ADR
                  ―
                  ―
                  E2XE34
                  Exelixis Inc Shs Unsponsored Brazilian Depositary Receipt Repr 0.5 Sh
                  ―
                  ―
                  J2AZ34
                  Jazz Pharmaceuticals PLC Unsponsored BDR
                  ―
                  ―
                  U2TH34
                  United Therapeutics Corporation Unsponsored Brazilian Depositary Receipt Repr 0.05
                  ―
                  ―
                  Compare BR:N1BI34 Stocks >
                  Popular Stocks